Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation (CHIPS)

September 17, 2024 updated by: Dongying Zhang

Efficacy and Safety of Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

The main purpose of the CHIPS trial is to evaluate the efficacy and safety of colchicine in heart failure with preserved ejection fraction (HFpEF) patients with inflammation, including the effects of colchicine on circulating inflammatory markers, cardiac structure, cardiac function, clinical symptoms and exercise capacity in HFpEF patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

HFpEF is a disease with complex pathophysiological mechanisms, and inflammation has been found to be strongly associated with the onset and progression of HFpEF. Anti-inflammatory treatments begin to cut a striking figure in cardiovascular disease therapy. The LoDoCo2 trial showed a significant prognostic improvement of colchicine in patients with chronic coronary artery disease, and the latest COLICA trial, showed that 8 weeks of colchicine treatment significantly reduced levels of circulating inflammatory markers in patients with decompensated heart failure without serious adverse effects. However, at present, the efficacy and safety of colchicine for the treatment of HFpEF remains unclear. The CHIPS trial is a multi-center, randomized, open-label clinical trial. The aim of the study is to evaluate the efficacy and safety of colchicine in patients with heart failure with preserved ejection fraction and inflammation. The investigators proposed to assess changes in KCCQ scores, NT-proBNP levels, echocardiography and plasma inflammatory marker levels in HFpEF patients treated with or without colchicine to evaluate the efficacy of colchicine in HFpEF treatment.

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Chongqing
      • Chongqing, Chongqing, China, 400000
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:
        • Contact:
        • Contact:
          • Junlong Chen, MD.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Left ventricular ejection fraction measured by echocardiography ≥ 50%
  • Objective evidence of structural of functional abnormalities measured by echocardiography: 1)LVMI≥95 g/m2 in female and ≥115 g/m2 in male or 2)LAVI greater than 29ml/m2 in sinus rhythm or greater than 40ml/m2 in atrial fibrillation or 3)Average E/e' greater than 14 or 4)TR velocity greater than 2.8 m/s
  • Patients with elevated NT-proBNP levels 24 hours after discontinuing intravenous diuretics: ≥300 pg/ml in patients with sinus heart rate; ≥600 pg/ml in patients with atrial fibrillation
  • Both outpatient and admitted patients can be considered for enrollment. All patients must occurred worsening heart failure event within 30 days prior to randomization and a current NYHA cardiac function class II-IV
  • Patients with CRP levels greater than 2mg/L
  • Patient agrees to join and signs a written informed consent form

Exclusion Criteria:

  • Received colchicine treatment within one month prior to randomization
  • Acute coronary syndrome within 3 months prior to randomization, or history of pacemaker implantation, PCI, CABG within 3 months
  • eGFR less than 25 mL/min/1.73 m2
  • Liver function Child-Pugh class B or C
  • Patient has a history of previous allergy to colchicine or dapagliflozin / empagliflozin
  • Heart failure due to the following reasons: pericardial disease, pericardial effusion, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and other rare cardiomyopathies such as Fabry disease
  • Combined diagnosis of gastric ulcer, ulcerative colitis, Crohn disease and other digestive disorders or combined gastrointestinal tumors
  • Plan to undergo cardiac surgery such as coronary revascularization, radiofrequency ablation of arrhythmias, valve replacement or other surgical procedures
  • Pregnant or breastfeeding women
  • The patient who is cognitively impaired and is unable to accurately complete the assessment and completion of the KCCQ scale with the assistance of a physician
  • Autoimmune diseases such as systemic lupus erythematosus, long-term adrenocorticotropic hormone treatment for other diseases such as Schihan syndrome, or need to accept immunosuppressive drugs and monoclonal antibodies such as IL-1 and IL-6
  • Patient with combined active solid tumor or hematological malignancy
  • Patient comorbidity with other conditions that may be confused with HFpEF symptoms, such as acute exacerbation of COPD
  • Admission with a well-defined infection (symptoms or pathogenetic evidence of infection, and leukocytes greater than 10*109/L)
  • Previously diagnosed with HFrEF (initial assessment of LVEF less than 40%) or diagnosed with LVimpEF

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Colchicine Treatment Group
This group is intended to include 100 patients, all of the patients will be given 5mg of once-daily the colchicine treatment on top of the SGLT2i treatment
Drug: Colchicine 0.5 MG Oral Tablet Once Daily
The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
No Intervention: Control Group
The group is intended to include 100 patients, all of the patients will be given standard SGLT2i treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in KCCQ-CS scores
Time Frame: Up to 12 weeks
Patients were assessed for symptom improvement by Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS)
Up to 12 weeks
Change in 6-MWD
Time Frame: Up to 12 weeks
Improvement in patients exercise capacity assessed by 6-minuet walk distance
Up to 12 weeks
Change in serum CRP levels
Time Frame: Up to 12 weeks
Change in serum C-reactive protein levels
Up to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in serum NT-proBNP levels
Time Frame: Up to 12 weeks
Change in serum N-terminal pro-B-type natriuretic peptide levels
Up to 12 weeks
Change in serum IL-1β levels
Time Frame: Up to 12 weeks
Change in serum interleukin-1β levels
Up to 12 weeks
Change in serum IL-6 levels
Time Frame: Up to 12 weeks
Change in serum interleukin-6 levels
Up to 12 weeks
Change in serum TNF-α levels
Time Frame: Up to 12 weeks
Change in serum tumor necrosis factor-α levels
Up to 12 weeks
Change in cardiac structure
Time Frame: Up to 12 weeks
Left ventricular mass index (LVMI) measured by echocardiography
Up to 12 weeks
Change in cardiac structure
Time Frame: Up to 12 weeks
Left atrial volume index (LAVI) measured by echocardiography
Up to 12 weeks
Change in cardiac structure
Time Frame: Up to 12 weeks
Left ventricular end-diastolic diameter (LVEDD) measured by echocardiography
Up to 12 weeks
Change in cardiac function
Time Frame: Up to 12 weeks
Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography
Up to 12 weeks
Change in cardiac function
Time Frame: Up to 12 weeks
Right ventricular ejection fraction (RVEF) measured by echocardiography
Up to 12 weeks
Change in cardiac function
Time Frame: Up to 12 weeks
Peak mitral inflow velocity and peak diastolic mitral annulus velocity measured by echocardiography
Up to 12 weeks
Change in cardiac function
Time Frame: Up to 12 weeks
Early diastolic mitral annular tissue velocity (e') measured by echocardiography
Up to 12 weeks
Worsening heart failure events
Time Frame: Up to 12 weeks
Time to first worsening heart failure events, including hospitalization due to heart failure or intravenous diuretic therapy
Up to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dongying Zhang

Collaborators

National Natural Science Foundation of China

Investigators

  • Study Chair: Dongying Zhang, MD. Ph.D., First Affiliated Hospital of Chongqing Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 31, 2024

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

March 31, 2026

Study Registration Dates

First Submitted

September 14, 2024

First Submitted That Met QC Criteria

September 17, 2024

First Posted (Estimated)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 17, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ChiPS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The next study will be conducted at the end of this study, so the data cannot be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Colchicine 0.5 MG Oral Tablet Once Daily

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe